Citron Research Updates Emcore (EMKR)

Today, Citron Research updated its opinion of Emcore (Nasdaq: EMKR). Citron is a widely followed short seller who has written negative pieces on Arthrocare (Nasdaq: ARTC), Home Solutions (OTCBB: HSOA) and others in the past. Ostensibly, his next target is Emcore.

Citron said Emcore is reminiscent of Home Solutions. Home Solutions now trades for under a $1. Citron believes that Emcore needs to become profitable to fix its problems.

Also, Citron said, if Emcore's Green and Gold Energy is revealed to be an 'empty shell,' Citron said Emcore would in turn miss its earnings. [JT]
Citron Research

Sign up at EasyStockAlerts.com & Make Money Today!

The Disciplined Investor - Essential Strategies for Success

You May Also Be Interested In

• Morgan Stanley lists top 10 AI stocks to buy in Europe
• 3 software infrastructure stocks to buy into Q2 earnings: Piper Sandler
• This EU name is becoming "a structural beneficiary of AI power infrastructure"